December 2022 in “bioRxiv (Cold Spring Harbor Laboratory)” The new vaccine platform led to a stronger immune response and better protection against the flu than the traditional vaccine.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
1 citations
,
October 2013 in “The Journal of Dermatology” Hair loss in a drug reaction case involved both a common shedding phase and an immune attack on hair follicle stem cells.
June 2007 in “Taiwan Journal of Ophthalmology” Young patients with Vogt-Koyanagi-Harada syndrome may have poor vision outcomes despite treatment due to frequent recurrences.
6 citations
,
May 2013 in “The Journal of Dermatology” Autoimmune reactions may cause both alopecia areata and HAM.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
September 2025 in “Annals of African Medicine” 2 citations
,
January 2022 in “JAAD Case Reports” The rash resolved after stopping ponatinib.
24 citations
,
June 2016 in “Acta dermato-venereologica” Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.
8 citations
,
September 2004 in “Contact dermatitis” Avoiding dyed wigs and clothing improved severe allergic reactions in a woman treated with diphencyprone.
2 citations
,
January 2002 in “Linchuang pifuke zazhi” Cyclosporine combination therapy can regrow hair in severe alopecia areata but needs careful monitoring for side effects.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
September 2019 in “Philippine Journal of Internal Medicine” Early immunosuppressive therapy leads to favorable outcomes in Filipino lupus patients with myocarditis.
April 2020 in “Trends in Immunotherapy” Combining triamcinolone acetonide and immunotherapy can help regrow hair in some alopecia totalis patients.
March 2026 in “SHILAP Revista de lepidopterología” Rituximab may cause skin issues, but baricitinib can help improve them.
32 citations
,
September 2015 in “Dermatology” Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.
5 citations
,
November 2012 in “Journal of Clinical Psychopharmacology” Valproic acid and isoniazid can interact, causing toxicity, so careful monitoring is needed.
23 citations
,
October 1958 in “PubMed”
July 2025 in “Russian Journal of Clinical Dermatology and Venereology” Tofacitinib may help hair regrowth in familial alopecia areata with immune issues, but more research is needed.
2 citations
,
March 2022 in “PubMed” Most skin reactions to COVID-19 vaccines in India were mild and not a reason to avoid vaccination.
21 citations
,
March 2002 in “PubMed” High-dose steroid pulse therapy effectively regrows hair in severe multifocal alopecia areata.
3 citations
,
February 2023 in “Journal of Infection and Public Health” More symptoms during initial COVID infection increase the risk of long-term effects.
10 citations
,
January 2018 in “Postępy Dermatologii i Alergologii” Treating alopecia areata every 3 weeks with diphenylcyclopropenone is more effective than weekly treatments.
20 citations
,
June 2019 in “JAAD Case Reports” Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.
May 2025 in “International Journal of Science and Research (IJSR)” Stopping azathioprine led to full hair regrowth and recovery in 2.5 months.
March 2016 in “International Journal of Infectious Diseases” Peginterferon alpha-2a effectively treats acute hepatitis C in hemodialysed patients, despite some side effects.
October 2023 in “Microorganisms” Nirmatrelvir/Ritonavir treatment may lead to a weaker immune response to COVID-19, but doesn't affect the chance of rebound.
88 citations
,
October 1983 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Patients with this syndrome can have different responses and worsening resistance to treatment over time.
26 citations
,
June 2020 in “The Journal of Allergy and Clinical Immunology In Practice” A patient developed a severe skin reaction and died after taking hydroxychloroquine for COVID-19.
27 citations
,
August 2024 in “Frontiers in Pharmacology” Tralokinumab for atopic dermatitis may cause side effects like dizziness, headache, nausea, hair loss, and acne.